Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Antonietta Pia Falcone
First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials
Haematologica
Hematology
Related publications
Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)
Clinical Cancer Research
Cancer Research
Oncology
Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cardiotoxicity Risk With Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity Matched Study of 1,790 Patients
American Journal of Hematology
Hematology
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Toxicity-Reduced, Myeloablative Allograft Followed by Lenalidomide Maintenance as Salvage Therapy for Refractory/Relapsed Myeloma Patients
Bone Marrow Transplantation
Transplantation
Hematology
